 OncLive | Everolimus Plus Tamoxifen Delivers Benefits in Hormone-Resistant mBC OncLive Combining tamoxifen with everolimus (Afinitor) increased the clinical benefit rate (CBR), time to progression (TTP), and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer (mBC) resistant to endocrine therapy, ... |
